The move impacts multinational drugmakers, like Abbott Laboratories and GlaxoSmithKline Plc, and a number of local firms, including Lupin Ltd, Cadila Healthcare Ltd and Ipca Ltd, all of whom sell drugs added to the list.
A notice posted on the National Pharmaceutical Pricing Authority (NPPA) website late on Wednesday detailed the 39 new drugs, which extend a price control list that already includes more than 652 medicines.
New drugs added to the list include commonly used antibiotics such as azithromycin, combinations of metformin for diabetes, as well as the anti-emetic domperidone.
Pharma in 2014: Deals worth billions and fines worth millions
Dilip Shanghvi's success: From a start-up to India's largest drug maker
PHOTOS: Biggest pharmaceutical companies in the world
How India bungled on foreign investor tax row
Delhi HC sets aside government decision to cap condom prices